News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Vasograin Plus represents a major advancement in the treatment of migraine
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated
